CNTA
NEUTRALM&ACentessa Pharmaceuticals plc
This is the 2026-05-19 snapshot — the signals and analysis for CNTA as of this single trading day.
View full CNTA research hub →Analysis
Centessa Pharmaceuticals (CNTA) is trading as a pure merger arbitrage vehicle following Eli Lilly's definitive agreement to acquire the company for $38.00 in cash plus a Contingent Value Right (CVR) of up to $9.00 per share. The stock's current price of $39.70 reflects the guaranteed cash floor plus approximately a 19% implied probability of the CVR milestones being met. Technical signals like QUIET_STORM perfectly align with the stock's microscopic 2.3% realized volatility as arbitrageurs lock in the spread. Furthermore, the broader RISK_ON macro regime and rock-bottom High Yield OAS (0.75%) eliminate any deal financing concerns, ensuring high institutional conviction in a Q3 2026 close.
Fired Signals
Key Takeaways
- Merger Arbitrage Pricing: At $39.70, the market is fully valuing the $38 base cash offer and pricing the $9 CVR at ~$1.70, capping near-term directional upside.
- Signal Alignment: The QUIET_STORM signal and 0.6x relative volume reflect institutional deal absorption and a complete decoupling from broader market beta.
- Clear Path to Close: With pristine macro credit conditions (0.75% HY OAS) and Lilly's deep pockets, deal financing risk is zero ahead of the June 12 shareholder vote.